文献速递造血干细胞移植与细胞治疗血栓与止血

重组人血小板生成素促进脐血移植后血小板植入

Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation.
PubMed 文献 · Blood Adv · 2020-01-01

这项随机对照研究将120例计划接受脐血移植的患者分为重组人血小板生成素(rhTPO)组(移植后第14至28天每日一次300 U/kg,n=60)和对照组(n=60),发现rhTPO组60天血小板植入累积发生率(83.1% vs 66.7%,P=.020)和120天血小板恢复累积发生率(81.4% vs 65.0%,P=.032)均显著高于对照组,且所需血小板输注单位数更少(6 vs 8单位,P=.026),无严重不良反应。

要点

  • rhTPO组60天血小板植入率83.1% vs 对照组66.7%(P=.020)。
  • rhTPO组120天血小板恢复率81.4% vs 对照组65.0%(P=.032)。
  • rhTPO组所需血小板输注单位数6 vs 对照组8(P=.026)。

核心结论

  • 研究表明rhTPO在患者中耐受良好,可有效促进脐血移植后血小板植入。

研究设计与样本

  • 随机对照研究,共120例计划接受脐血移植的患者随机分为rhTPO组(300 U/kg每日一次,脐血移植后第14至28天给药,n=60)和对照组(n=60)。
  • 主要终点为单份脐血移植后60天血小板植入累积发生率。
  • 研究在中国临床试验注册中心注册,注册号ChiCTR-IPR-16009357。

主要发现

  • 60天血小板植入(血小板计数≥20×10^9/L)累积发生率rhTPO组83.1% vs 对照组66.7%(P=.020)。
  • 120天血小板恢复(血小板计数≥50×10^9/L)累积发生率rhTPO组81.4% vs 对照组65.0%(P=.032)。
  • 所需血小板输注单位数rhTPO组6 vs 对照组8(P=.026)。
  • 中性粒细胞植入累积发生率、2年总生存率、无病生存率及无移植物抗宿主病无复发生存率两组间无差异。
  • 其他移植相关结局和并发症两组间无差异,接受rhTPO的患者未观察到严重不良反应。

临床怎么用

  • 原文结论为rhTPO在患者中耐受良好,可有效促进脐血移植后血小板植入。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Delayed platelet engraftment is a common complication after umbilical cord blood transplantation (UCBT) accompanied by increased transplant-related complications or death. This study was designed to determine the safety and efficacy of recombinant human thrombopoietin (rhTPO) in promoting platelet engraftment after UCBT. A total of 120 patients scheduled to receive UCBT were randomly assigned to the rhTPO group (300 U/kg once daily from days 14 to 28 after UCBT, n = 60) or the control group (n = 60). The primary outcome was the 60-day cumulative incidence of platelet engraftment after single-unit cord blood transplantation. The 60-day cumulative incidence of platelet engraftment (platelet count ≥20 × 109/L) and the 120-day cumulative incidence of platelet recovery (platelet count ≥50 × 109/L) were both significantly higher in the rhTPO group than in the control group (83.1% vs 66.7%, P = .020; and 81.4% vs 65.0%, P = .032, respectively). In addition, the number of required platelet infusions was significantly lower in the rhTPO group than in the control group (6 vs 8 units, respectively; P = .026). The cumulative incidence of neutrophil engraftment and the probability of 2-year overall survival, disease-free survival, and graft-versus-host disease-free relapse-free survival did not differ between the 2 groups. Other transplant-related outcomes and complications did not differ between the 2 groups, and no severe adverse effects were observed in patients receiving rhTPO. This study demonstrated that rhTPO is well tolerated in patients and could effectively promote platelet engraftment after UCBT. This study was registered on the Chinese Clinical Trial Registry (http://www.chictr.org.cn/index.aspx) as ChiCTR-IPR-16009357.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tang B, Huang L, Liu H, et al. Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation. Blood Adv. 2020. PMID: 32790845. doi:10.1182/bloodadvances.2020002257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。